A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 15, 2012

Primary Completion Date

June 15, 2015

Study Completion Date

October 12, 2018

Conditions
Ovarian Neoplasms
Interventions
DRUG

Carboplatin

carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])

DRUG

Paclitaxel

Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])

BIOLOGICAL

oregovomab

oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).

Trial Locations (2)

46601

Northern Indiana Cancer Research Consortium, South Bend

06030

University of Connecticut Health Center, Farmington

All Listed Sponsors
lead

Quest PharmaTech Inc.

INDUSTRY

NCT01616303 - A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter